The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets
Open accessAbstract
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumour in humans and has a very poor prognosis. The existing treatments have had limited success in increasing overall survival. Thus, identifying and understanding the key molecule(s) responsible for the malignant phenotype of GBM will yield new potential therapeutic targets. The treatment of brain tumours faces unique challenges, including the presence of the blood brain barrier (BBB), which limits the concentration of drugs that can reach the site of the tumour. Nevertheless, several promising treatments have been shown to cross the BBB and have shown promising pre-clinical results. This review will outline the status of several of these promising targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Gravina, G. L., Mancini, A., Colapietro, A., Monache, S. D., Sferra, R., Vitale, F., Cristiano, L., Martellucci, S., Marampon, F., Mattei, V., et al. (2019) · Cancers · doi:10.3390/cancers11030359 · Cited by 53
RetractedMa, C., Li, Y., Zhang, X., Zhao, G., & Xu, H. (2014) · Journal of International Medical Research · doi:10.1177/0300060513481924 · Cited by 18
RetractedRadiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Brocken, P., van der Heijden, H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus-Oei, L.-F. (2014) · Respiration · doi:10.1159/000347096 · Cited by 4,002
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Ostrom, Q. T., Gittleman, H., Fulop, J., Liu, M., Blanda, R., Kromer, C., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov189 · Cited by 2,139
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Glioblastoma: Overview of Disease and Treatment
Davis, M. (2016) · Clinical Journal of Oncology Nursing · doi:10.1188/16.cjon.s1.2-8 · Cited by 1,205
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Weller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767
Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Lee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 677
An, Z., Aksoy, O., Zheng, T., Fan, Q.-W., & Weiss, W. A. (2018) · Oncogene · doi:10.1038/s41388-017-0045-7 · Cited by 668
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 655
IDH1 and IDH2 mutations in gliomas
Cohen, A. L., Holmen, S. L., & Colman, H. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0345-4 · Cited by 629
Primary and secondary glioblastomas: From concept to clinical diagnosis
Kleihues, P., & Ohgaki, H. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.44 · Cited by 586
Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E., & Collins, V. P. (1993) · PubMed · Cited by 560
Overcoming therapeutic resistance in glioblastoma: the way forward
Osuka, S., & Van Meir, E. G. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89587 · Cited by 511
Structure and Function of VEGF/VEGF-receptor System Involved in Angiogenesis.
Shibuya, M. (2001) · Cell Structure and Function · doi:10.1247/csf.26.25 · Cited by 504
Plate, K. H., Breier, G., Millauer, B., Ullrich, A., & Risau, W. (1993) · PubMed · Cited by 498
The EGFRvIII variant in glioblastoma multiforme
Gan, H. K., Kaye, A. H., & Luwor, R. B. (2009) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2008.12.005 · Cited by 396
Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma
Furnari, F. B., Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3918 · Cited by 381
Prados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378
Kilic, T., Alberta, J. A., Zdunek, P. R., Acar, M., Iannarelli, P., O'Reilly, T., Buchdunger, E., Black, P. M., & Stiles, C. D. (2000) · PubMed · Cited by 310
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
Abounader, R., & Laterra, J. (2005) · Neuro-Oncology · doi:10.1215/s1152851705000050 · Cited by 300
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K. A., Wen, P. Y., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop015 · Cited by 299
Nonsurgical Treatment of Recurrent Glioblastoma
Gallego, O. (2015) · Current Oncology · doi:10.3747/co.22.2436 · Cited by 296
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma
SongTao, Q., Lei, Y., Si, G., YanQing, D., HuiXia, H., XueLin, Z., LanXiao, W., & Fei, Y. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2011.02134.x · Cited by 294
Das, S., & Marsden, P. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmcibr1309402 · Cited by 268
Burger, M. T., Pecchi, S., Wagman, A., Ni, Z.-J., Knapp, M., Hendrickson, T., Atallah, G., Pfister, K., Zhang, Y., Bartulis, S., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200156t · Cited by 252
Zhao, H.-F., Wang, J., Shao, W., Wu, C.-P., Chen, Z.-P., To, S.-S. T., & Li, W.-P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0670-3 · Cited by 251
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J.-F., D'Hondt, L., Strauven, T., Chaskis, C., In't Veld, P., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 250
Raymond, E., Brandes, A. A., Dittrich, C., Fumoleau, P., Coudert, B., Clement, P. M. J., Frenay, M., Rampling, R., Stupp, R., Kros, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9235 · Cited by 227
Current data and strategy in glioblastoma multiforme.
Iacob, G., & Dinca, E. B. (2009) · PubMed Central · Cited by 225
Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier.
Kakee, A., Terasaki, T., & Sugiyama, Y. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13107-8 · Cited by 225
Iwamoto, F. M., Lamborn, K. R., Robins, H. I., Mehta, M. P., Chang, S. M., Butowski, N. A., DeAngelis, L. M., Abrey, L. E., Zhang, W.-T., Prados, M. D., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq025 · Cited by 223
EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme
Day, B. W., Stringer, B. W., Al-Ejeh, F., Ting, M. J., Wilson, J., Ensbey, K. S., Jamieson, P. R., Bruce, Z. C., Lim, Y. C., Offenhäuser, C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.007 · Cited by 218
Felsberg, J., Rapp, M., Loeser, S., Fimmers, R., Stummer, W., Goeppert, M., Steiger, H.-J., Friedensdorf, B., Reifenberger, G., & Sabel, M. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2801 · Cited by 203
Sarkaria, J. N., Yang, L., Grogan, P. T., Kitange, G. J., Carlson, B. L., Schroeder, M. A., Galanis, E., Giannini, C., Wu, W., Dinca, E. B., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0691 · Cited by 200
Hegi, M. E., Diserens, A.-C., Bady, P., Kamoshima, Y., Kouwenhoven, M. C. M., Delorenzi, M., Lambiv, W. L., Hamou, M.-F., Matter, M. S., Koch, A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0048 · Cited by 194
Uhm, J. H., Ballman, K. V., Wu, W., Giannini, C., Krauss, J. C., Buckner, J. C., James, C. D., Scheithauer, B. W., Behrens, R. J., Flynn, P. J., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.070 · Cited by 192
Prognostic significance of c‐Met expression in glioblastomas
Kong, D., Song, S., Kim, D., Joo, K. M., Yoo, J., Koh, J. S., Dong, S. M., Suh, Y., Lee, J., Park, K., et al. (2009) · Cancer · doi:10.1002/cncr.23972 · Cited by 187
PDGF and PDGF receptors in glioma
Nazarenko, I., Hede, S.-M., He, X., Hedrén, A., Thompson, J., Lindström, M. S., & Nistér, M. (2012) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.665097 · Cited by 183
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
de Boüard, S., Herlin, P., Christensen, J. G., Lemoisson, E., Gauduchon, P., Raymond, E., & Guillamo, J.-S. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-024 · Cited by 180
Primary Brain Tumors in Adults: Diagnosis and Treatment.
Perkins, A., & Liu, G. (2016) · PubMed · Cited by 178
Chakravarti, A., Wang, M., Robins, H. I., Lautenschlaeger, T., Curran, W. J., Brachman, D. G., Schultz, C. J., Choucair, A., Dolled-Filhart, M., Christiansen, J., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.10.008 · Cited by 177
Koul, D., Fu, J., Shen, R., LaFortune, T. A., Wang, S., Tiao, N., Kim, Y.-W., Liu, J.-L., Ramnarian, D., Yuan, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1558 · Cited by 171
Wen, P. Y., Touat, M., Alexander, B. M., Mellinghoff, I. K., Ramkissoon, S., McCluskey, C. S., Pelton, K., Haidar, S., Basu, S. S., Gaffey, S. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01207 · Cited by 169
PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme
Gallia, G. L., Rand, V., Siu, I.-M., Eberhart, C. G., James, C. D., Marie, S. K. N., Oba-Shinjo, S. M., Carlotti, C. G., Caballero, O. L., Simpson, A. J. G., et al. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0172 · Cited by 161
Benítez, J. A., Ma, J., D’Antonio, M., Boyer, A. D., Camargo, M. F., Zanca, C., Kelly, S., Khodadadi‐Jamayran, A., Jameson, N. M., Andersen, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15223 · Cited by 160
Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.
Russell, J. S., Brady, K. J., Burgan, W. E., Cerra, M. A., Oswald, K. A., Camphausen, K. A., & Tofilon, P. J. (2003) · PubMed · Cited by 157
Dresemann, G. P., Weller, M., Rosenthal, M. A., Wedding, U., Wagner, W., Engel, E., Heinrich, B., Mayer‐Steinacker, R., Krarup‐Hansen, A., Fluge, Ø., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9976-3 · Cited by 156
Goßmann, A., Helbich, T. H., Kuriyama, N., Ostrowitzki, S., Roberts, T. P. L., Shames, D. M., van Bruggen, N., Wendland, M. F., Israel, M. A., & Brasch, R. C. (2002) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.10072 · Cited by 151
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells
Hertler, C., Roth, P., Wick, W., Schmidt, N., Florea, A., Silginer, M., Reifenberger, G., & Weller, M. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07781.x · Cited by 144
Griffero, F., Daga, A., Marubbi, D., Capra, M. C., Melotti, A., Pattarozzi, A., Gatti, M., Bajetto, A., Porcile, C., Barbieri, F., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807111200 · Cited by 140
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
Yung, W. K. A., Vredenburgh, J. J., Cloughesy, T. F., Nghiemphu, P. L., Klencke, B. J., GILBERT, M. R., Reardon, D. A., & Prados, M. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq072 · Cited by 140
Hainsworth, J. D., Ervin, T. J., Friedman, E. K., Priego, V. M., Murphy, P. B., Clark, B. L., & Lamar, R. E. (2010) · Cancer · doi:10.1002/cncr.25275 · Cited by 131
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma
Koul, D., Shen, R., Kim, Y., Kondo, Y., Lu, Y., Bankson, J. A., Ronen, S. M., Kirkpatrick, D. L., Powis, G., & Yung, W. K. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop058 · Cited by 130
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
Miyamoto, M., Ojima, H., Iwasaki, M., Shimizu, H., Kokubu, A., Hiraoka, N., Kosuge, T., Yoshikawa, D., Kono, T., Furukawa, H., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.199 · Cited by 129
Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells
Gan, H. K., van den Bent, M. J., Lassman, A. B., Reardon, D. A., & Scott, A. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.95 · Cited by 126
Phase II study of PX-866 in recurrent glioblastoma
Pitz, M. W., Eisenhauer, E. A., MacNeil, M. V., Thiessen, B. A., Easaw, J. C., Macdonald, D. R., Eisenstat, D. D., Kakumanu, A. S., Salim, M., Chalchal, H. I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou365 · Cited by 121
Khurana, V. G., Jain, S., Smee, R., Cook, R., Dobes, M., Shadbolt, B., Smith, S., & Dexter, M. A. J. (2011) · Surgical Neurology International · doi:10.4103/2152-7806.90696 · Cited by 115
Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
Eller, J. L., Longo, S. L., Kyle, M. M., Bassano, D. A., Hicklin, D. J., & Canute, G. W. (2005) · Neurosurgery · doi:10.1227/01.neu.0000145865.25689.55 · Cited by 110
Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy
Yi, Y., Hsieh, I.-Y., Huang, X., Li, J., & Zhao, W. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00477 · Cited by 105
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
Welsh, J. W., Mahadevan, D., Ellsworth, R., Cooke, L. S., Bearss, D. J., & Stea, B. (2009) · Radiation Oncology · doi:10.1186/1748-717x-4-69 · Cited by 104
A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor–expressing tumor cells
Wykosky, J., Gibo, D. M., & Debinski, W. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0200 · Cited by 94
Zhu, P., Du, X. L., Lu, G., & Zhu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17054 · Cited by 94
Biology, genetics and imaging of glial cell tumours
Walker, C. A., Baborie, A., Crooks, D. A., Wilkins, S., & Jenkinson, M. D. (2011) · British Journal of Radiology · doi:10.1259/bjr/23430927 · Cited by 91
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Kalpathy–Cramer, J., Chandra, V., Da, X., Ou, Y., Emblem, K. E., Muzikansky, A., Cai, X., Douw, L., Evans, J. G., Dietrich, J., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2332-5 · Cited by 84
Cantanhede, I. G., & de Oliveira, J. R. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15045-w · Cited by 84
Prognostic significance of epidermal growth factor receptor expression in glioma patients
Li, J., Liang, R., Chen, S., Xiang, Y., & Liu, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s155160 · Cited by 84
Halatsch, M., Gehrke, E. E., Vougioukas, V. I., Bötefür, I. C., Borhani, F. A., Efferth, T., Gebhart, E., Domhof, S., Schmidt, U. I., & Buchfelder, M. (2004) · Journal of neurosurgery · doi:10.3171/jns.2004.100.3.0523 · Cited by 83
Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma
Koschmann, C. J., Zamler, D. B., Mackay, A. G., Robinson, D. R., Wu, Y.-M., Doherty, R. E., Marini, B. L., Tran, D., Garton, H. J. L., Muraszko, K. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11602 · Cited by 83
Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
Cruickshanks, N. A., Zhang, Y., Yuan, F., Pahuski, M., Gibert, M. K., & Abounader, R. (2017) · Cancers · doi:10.3390/cancers9070087 · Cited by 74
High levels of c-Met is associated with poor prognosis in glioblastoma
Petterson, S. A., Dahlrot, R. H., Hermansen, S. K., Munthe, S., Gundesen, M. T., Wohlleben, H., Rasmussen, T., Beier, C. P., Hansen, S., & Kristensen, B. W. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1723-3 · Cited by 73
Development of targeted therapies in treatment of glioblastoma.
Xu, Y., Gao, P., Sun, Y., & Duan, Y. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0020 · Cited by 70
Qazi, M. A., Vora, P., Venugopal, C., Adams, J., Singh, M., Hu, A., Gorelik, M., Subapanditha, M., Savage, N. J., Yang, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0267 · Cited by 63
Simultaneous targeting of Eph receptors in glioblastoma
Ferluga, S., Tomé, C. M. L., Herpai, D., D'Agostino, R., & Debinski, W. (2016) · Oncotarget · doi:10.18632/oncotarget.10978 · Cited by 57
Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma
Parker, J. J., Dionne, K. R., Massarwa, R., Klaassen, M., Foreman, N. K., Niswander, L. A., Canoll, P., Kleinschmidt-DeMasters, B. K., & Waziri, A. E. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not053 · Cited by 56
New approaches to primary brain tumor treatment
Sathornsumetee, S., & Rich, J. N. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000231473.00030.1f · Cited by 55
STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma
Geng, L., Shinohara, E. T., Kim, D., Tan, J., Osusky, K. L., Shyr, Y., & Hallahan, D. E. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.08.025 · Cited by 54
An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth
Guessous, F., Zhang, Y., diPierro, C. G., Marcinkiewicz, L., Sarkaria, J. N., Schiff, D., Buchanan, S. G., & Abounader, R. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611009010028 · Cited by 54
C-MET overexpression and amplification in gliomas.
Kwak, Y., Kim, S. I., Park, C., Paek, S. H., Lee, S., & Park, S. (2015) · PubMed Central · Cited by 54
Rath, P., Lal, B., Ajala, O., Li, Y.-Q., Xia, S., Kim, J., & Laterra, J. (2013) · Translational Oncology · doi:10.1593/tlo.13127 · Cited by 52
Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy
Joshi, A. D., Loilome, W., Siu, I., Tyler, B., Gallia, G. L., & Riggins, G. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044372 · Cited by 46
Navis, A. C., van Lith, S. A. M., van Duijnhoven, S. M. J., de Pooter, M., Yetkin-Arik, B., Wesseling, P., Hendriks, W. J. A. J., Venselaar, H., Timmer, M., van Cleef, P., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1420-5 · Cited by 45
Yang, S., Gao, K.-D., Jiang, T., Cheng, S., & Li, W. (2017) · Oncotarget · doi:10.18632/oncotarget.16924 · Cited by 43
EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines
Chakravarty, D., Pedraza, A. M., Cotari, J. W., Liu, A. H.-C., Punko, D., Kokroo, A., Huse, J. T., Altan-Bonnet, G. Y., & Brennan, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-08940-9 · Cited by 43
EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma
Offenhäuser, C., Al‐Ejeh, F., Puttick, S. G., Ensbey, K. S., Bruce, Z. C., Jamieson, P. R., Smith, F. M., Stringer, B. W., Carrington, B., Fuchs, A. V., et al. (2018) · Cancers · doi:10.3390/cancers10120519 · Cited by 42
Tumour treating fields in a combinational therapeutic approach
Branter, J., Basu, S., & Smith, S. J. (2018) · Oncotarget · doi:10.18632/oncotarget.26344 · Cited by 37
Grisanti, S., Bresciano, O. B. O. T. G. N.-O., Ferrari, V. D., Buglione, M., Agazzi, G. M., Liserre, R., Poliani, P. L., Buttolo, L., Gipponi, S., Pedersini, R., et al. (2019) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.16.03874-1 · Cited by 34
Shen, D., Liu, T., Lin, Q., Lu, X., Wang, Q., Lin, F., & Mao, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107558 · Cited by 32
The future role of personalized medicine in the treatment of glioblastoma multiforme
Adamson, C. (2010) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s6852 · Cited by 32
Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts
Goodwin, C. R., Rath, P., Oyinlade, O., López-Bertoni, H., Mughal, S., Xia, S., Li, Y.-Q., Kaur, H., Zhou, X., Ahmed, A. K., et al. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.02.041 · Cited by 32
Gwak, H., Shingu, T., Chumbalkar, V. C., Hwang, Y., Dejournett, R. E., Latha, K., Koul, D., Yung, W. K. A., Powis, G., Farrell, N. P., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25394 · Cited by 25
Latzer, P., Shchyglo, O., Hartl, T., Matschke, V., Schlegel, U. S., Manahan‐Vaughan, D., & Theiß, C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00113 · Cited by 24
The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma
D’Amico, R. S., Lei, L., Kennedy, B. C., Sisti, J. S., Ebiana, V., Crisman, C., Christensen, J. G., Gil, O. D., Rosenfeld, S. S., Canoll, P., et al. (2012) · Neurological Research · doi:10.1179/1743132812y.0000000005 · Cited by 20
Cited by
Tomar, M. S., Kumar, A., Srivastava, C., & Shrivastava, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188616 · Cited by 325
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15072116 · Cited by 293
Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives
Seker-Polat, F., Pinarbasi Degirmenci, N., Solaroglu, I., & Bagci-Onder, T. (2022) · Cancers · doi:10.3390/cancers14020443 · Cited by 253
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Metadata
- Authors
- Taylor, O. G., Brzozowski, J. S., & Skelding, K. A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2019-09-26
- Volume
- 9
- Pages
- 963-963
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2975525011
- Cited by
- 322
- References
- 108
- FWCI
- 20.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.